In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.

Inclusion Criteria:

• Clinical diagnosis of Breast cancer
• Received standard treatment (chemotherapy, operation, or radiotherapy)
• premenopausal
• estrogen and/or progesterone receptor positive

Exclusion Criteria:

• Metastatic tumors
• During pregnancy or lactation